Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG

Study Identifier:
D7411C00003
ClinicalTrials.gov Identifier:
NCT06764160
EudraCT Identifier:
N/A
EU CT ID:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Recruitment Complete

Study Details

Medical Condition
  • Generalized Myasthenia Gravis (gMG)
  • Unmapped
Study Drug
  • Drug: Eculizumab
Date
Jan 2025 - Dec 2025
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Inclusion and Exclusion Criteria
Inclusion Criteria
  • Diagnosis of MG must be made by the following tests:
  • Positive serologic test for anti-AChR Abs as confirmed at Screening, and
  • One of the following:
  • Abnormal neuromuscular transmission demonstrated by repetitive nerve stimulation, or
  • History of positive anticholinesterase test, eg, neostigmine test, or
  • Participant has demonstrated improvement in MG signs on oral cholinesterase inhibitors as assessed by the treating physician
  • MGFA Clinical Classification Class II to IV at Screening
  • MG-ADL total score must be ≥ 6 at Screening and Day 1
  • Participants who have:
  • Failed treatment with 2 or more ISTs over one year (either in combination or as monotherapy), ie, continue to have impairment ADLs (persistent weakness, experience crisis, or unable to tolerate IST) despite ISTs or,
  • Failed at least one IST and require chronic PE or IVIg to control symptoms, ie, participants who require PE or IVIg on a regular basis for the management of muscle weakness at least 2 cycles over last 12 months
Exclusion Criteria
  • Any untreated thymic malignancy, carcinoma, or thymoma
  • History of thymectomy or any other thymic surgery within 6 months prior to Screening. Participants with a history of treated thymic malignancy or carcinoma are eligible if they meet all of the following conditions:
  • Treatment completed \> 5 years prior to the Screening Visit
  • No recurrence within the 5 years prior to the Screening Visit
  • No radiological indication of recurrence in a computed tomography (CT) or magnetic resonance imaging (MRI) scan, including administration of intravenous (IV) contrast, performed within 6 months of first dose on Day 1
  • Weakness only affecting ocular or peri-ocular muscles (MGFA Class I)
  • MG crisis at Screening (MGFA Class V). However, such participants may be rescreened with Alexion approval once they are treated and medically stable, in the opinion of the Investigator
  • History of N meningitidis infection or unresolved meningococcal disease
Sex
Female & Male
Age
18+ years

Study Details

Medical Condition
  • Generalized Myasthenia Gravis (gMG)
  • Unmapped
Study Drug
  • Drug: Eculizumab
Date
Jan 2025 - Dec 2025
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information
Inclusion and Exclusion Criteria
Inclusion Criteria
  • Diagnosis of MG must be made by the following tests:
  • Positive serologic test for anti-AChR Abs as confirmed at Screening, and
  • One of the following:
  • Abnormal neuromuscular transmission demonstrated by repetitive nerve stimulation, or
  • History of positive anticholinesterase test, eg, neostigmine test, or
  • Participant has demonstrated improvement in MG signs on oral cholinesterase inhibitors as assessed by the treating physician
  • MGFA Clinical Classification Class II to IV at Screening
  • MG-ADL total score must be ≥ 6 at Screening and Day 1
  • Participants who have:
  • Failed treatment with 2 or more ISTs over one year (either in combination or as monotherapy), ie, continue to have impairment ADLs (persistent weakness, experience crisis, or unable to tolerate IST) despite ISTs or,
  • Failed at least one IST and require chronic PE or IVIg to control symptoms, ie, participants who require PE or IVIg on a regular basis for the management of muscle weakness at least 2 cycles over last 12 months
Exclusion Criteria
  • Any untreated thymic malignancy, carcinoma, or thymoma
  • History of thymectomy or any other thymic surgery within 6 months prior to Screening. Participants with a history of treated thymic malignancy or carcinoma are eligible if they meet all of the following conditions:
  • Treatment completed \> 5 years prior to the Screening Visit
  • No recurrence within the 5 years prior to the Screening Visit
  • No radiological indication of recurrence in a computed tomography (CT) or magnetic resonance imaging (MRI) scan, including administration of intravenous (IV) contrast, performed within 6 months of first dose on Day 1
  • Weakness only affecting ocular or peri-ocular muscles (MGFA Class I)
  • MG crisis at Screening (MGFA Class V). However, such participants may be rescreened with Alexion approval once they are treated and medically stable, in the opinion of the Investigator
  • History of N meningitidis infection or unresolved meningococcal disease

Protocol Summary

This is an open-label, single-arm, multi-center study to evaluate the efficacy, safety, PK, PD, and immunogenicity of eculizumab in Chinese participants with refractory gMG. Approximately 15 participants will be enrolled in the study.

Trial Locations

Location
Status
Location
Research Site
Changchun, China, 130021
Status
N/A
Location
Research Site
Changsha, China, 410008
Status
N/A
Location
Research Site
Fuzhou, China, 350001
Status
N/A
Location
Research Site
Guangzhou, China, 510080
Status
N/A
Location
Research Site
Guangzhou, China, 510620
Status
N/A
Location
Research Site
Qingdao, China, 266035
Status
N/A
Go to page